[go: up one dir, main page]

GB202409801D0 - Products for use in the treatment and prevention of allergy and associated lung conditions/diseases - Google Patents

Products for use in the treatment and prevention of allergy and associated lung conditions/diseases

Info

Publication number
GB202409801D0
GB202409801D0 GBGB2409801.4A GB202409801A GB202409801D0 GB 202409801 D0 GB202409801 D0 GB 202409801D0 GB 202409801 A GB202409801 A GB 202409801A GB 202409801 D0 GB202409801 D0 GB 202409801D0
Authority
GB
United Kingdom
Prior art keywords
allergy
diseases
prevention
products
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2409801.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Balance Therapeutics GmbH
Original Assignee
T Balance Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Balance Therapeutics GmbH filed Critical T Balance Therapeutics GmbH
Priority to GBGB2409801.4A priority Critical patent/GB202409801D0/en
Publication of GB202409801D0 publication Critical patent/GB202409801D0/en
Priority to PCT/EP2025/069197 priority patent/WO2026008865A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70514CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB2409801.4A 2024-07-05 2024-07-05 Products for use in the treatment and prevention of allergy and associated lung conditions/diseases Pending GB202409801D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2409801.4A GB202409801D0 (en) 2024-07-05 2024-07-05 Products for use in the treatment and prevention of allergy and associated lung conditions/diseases
PCT/EP2025/069197 WO2026008865A1 (en) 2024-07-05 2025-07-04 Products for use in the treatment and prevention of allergy and lung conditions/diseases associated with an allergy or with a pathogen-driven immune response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2409801.4A GB202409801D0 (en) 2024-07-05 2024-07-05 Products for use in the treatment and prevention of allergy and associated lung conditions/diseases

Publications (1)

Publication Number Publication Date
GB202409801D0 true GB202409801D0 (en) 2024-08-21

Family

ID=92301674

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2409801.4A Pending GB202409801D0 (en) 2024-07-05 2024-07-05 Products for use in the treatment and prevention of allergy and associated lung conditions/diseases

Country Status (2)

Country Link
GB (1) GB202409801D0 (en)
WO (1) WO2026008865A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540013C2 (en) 2008-03-13 2015-01-27 Биотест Аг Agent for treating disease
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP3957364A1 (en) * 2020-08-20 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
GB202017681D0 (en) * 2020-11-09 2020-12-23 T Balance Therapeutics Gmbh Anti-CD4 antibody or fragment thereof for medical use

Also Published As

Publication number Publication date
WO2026008865A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
IL316464A (en) Use of hpk1 inhibitor in prevention and/or treatment of human pathogen infection
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
ZA202303863B (en) New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
IL309317A (en) Treatment of mtres1 related diseases and disorders
EP4291233A4 (en) Polypeptides and their use in treatment of disease
GB202409801D0 (en) Products for use in the treatment and prevention of allergy and associated lung conditions/diseases
IL321373A (en) Treatment of mst1 related diseases and disorders
PL3937948T3 (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
EP4017496A4 (en) Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases
PT4364731T (en) Composition for use in the treatment of disrupted nasal mucosa and epithelial barrier
EP4171746A4 (en) Materials and methods for the prevention and treatment of viral respiratory diseases
EP4355355A4 (en) Treatment of plin1 related diseases and disorders
GB2610895C (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202202541D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease
IL300096A (en) Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
HK40112895A (en) Oximes and their use in treatment of gba-related diseases
GB202217453D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
GB202208255D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
GB202208256D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
CA3260002A1 (en) Compositions comprising amino acids for use in the prevention and/or treatment of intestinal diseases
GB202107297D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease
HK40100307A (en) Treatment and prevention of conditions associated with respiratory diseases
HK40093071A (en) Treatment and prevention of conditions associated with respiratory diseases
IL321120A (en) Treatment of mtres1 related diseases and disorders